SeaStar Medical Advances SCD Therapy for AKI and Severe Heart Failure.

• SeaStar Medical to expand revenue with QUELIMMUNE for ultra-rare pediatric AKI • Doubling customer base expected • SCD therapy for adult AKI indication could reach $4.5 billion market • NEUTRALIZE-AKI pivotal trial enrollment completed • PMA process initiated • SCD therapy in severe heart failure patients under development • Additional FDA designations for rapid commercialization